Molecular diagnostics company BillionToOne (BLLN.US) applies for US stock market IPO with plans to raise $100 million.

The molecular diagnostics company BillionToOne (focused on developing prenatal and oncology diagnostic technologies based on single-molecule sequencing platform) submitted an application to the U.S. Securities and Exchange Commission (SEC) on Tuesday, planning to raise up to $100 million through an initial public offering (IPO). BillionToOne focuses on the field of molecular diagnostics, developing prenatal and tumor detection products based on its single molecule next-generation sequencing (smNGS) platform a simple blood draw can provide clinically significant test results. In 2019, the company launched its first prenatal test product UNITY, the world's first non-invasive prenatal test technology based on cell-free DNA, which can assess the risk of hidden diseases in fetuses without requiring a sample from the father or invasive procedures. In 2023, the company further introduced two complementary liquid biopsy cancer detection products: Northstar Select, used for guiding treatment selection, and Northstar Response, based on methylation technology and quantifying cancer load at the single molecule level without the need for tissue biopsy. Headquartered in Menlo Park, California, the company was founded in 2016 and generated $209 million in revenue for the 12 months ending June 30, 2025. The company plans to list on the Nasdaq Stock Exchange under the ticker symbol "BLLN". BillionToOne had previously submitted its IPO application confidentially on June 20, 2025. The joint bookrunners for the transaction include J.P. Morgan, Piper Sandler, Jefferies, William Blair, Stifel, Guggenheim Securities, and BTIG. The company has not yet disclosed the pricing terms of the IPO.